Zobrazeno 1 - 10
of 83
pro vyhledávání: '"James, Ohr"'
Autor:
Steven Borson, Yongli Shuai, Barton F. Branstetter, Marci Lee Nilsen, Marion A. Hughes, Moon Fenton, Mark Kubik, Shaum Sridharan, David A. Clump, Heath D. Skinner, Jonas T. Johnson, Simion I. Chiosea, James Ohr, Umamaheswar Duvvuri, Seungwon Kim, Katie S. Traylor, Robert Ferris, Dan P. Zandberg
Publikováno v:
Laryngoscope Investigative Otolaryngology, Vol 7, Iss 3, Pp 757-765 (2022)
Abstract Objectives Data on the efficacy of including definitive local therapy to the primary site for head and neck squamous cell carcinoma (HNSCC) patients with synchronous distant metastasis are lacking. In multiple different solid tumor types, th
Externí odkaz:
https://doaj.org/article/8e063f3a91944f3ebecff1d2f616b066
Autor:
Joel Thomas, Hong Wang, David A. Clump, Robert L. Ferris, Umamaheswar Duvvuri, James Ohr, Dwight E. Heron
Publikováno v:
Frontiers in Oncology, Vol 10 (2020)
Objectives: Long-term quality-of-life data following stereotactic body radiation therapy (SBRT) for recurrent head and neck cancer (rHNC) is underreported. We report patient-reported quality-of-life (PR-QOL) after at least 1 year post-treatment.Metho
Externí odkaz:
https://doaj.org/article/e78bf4c0c65e42adb7b137a62e1611ae
Autor:
Marie-Nicole Theodoraki, Saigopalakrishna Yerneni, William E. Gooding, James Ohr, David A. Clump, Julie E. Bauman, Robert L. Ferris, Theresa L. Whiteside
Publikováno v:
OncoImmunology, Vol 8, Iss 7 (2019)
Purpose: Exosomes, small extracellular vesicles (EVs) derived from the endocytic compartment of their parent cells, are present in plasma of cancer patients and may serve as non-invasive biomarkers of disease outcome. Here, we asked whether tumor-der
Externí odkaz:
https://doaj.org/article/4acae28eaf8243e3b388efec97ff9e02
Autor:
Robert L. Ferris, Robert M. Hershberg, Jonas T. Johnson, Dwight E. Heron, David A. Clump, Umamaheswar Duvvuri, Seungwon Kim, James Ohr, Julie E. Bauman, James Kyle Bryan, Raghvendra M. Srivastava, Sandra P. Gibson, Benjamin A. Kansy, Gulidanna Shayan
Supplementary figure S1: IL-10, IL-1RA and Eotaxin plasma concentration in patients pre- vs. post-treatment with Cetuximab plus motolimod. Supplementary table S1: 95% confidence interval for figure 5 comparing pre vs post treatment expression changes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::773dc1a388d6eb14b75f67a82e87c581
https://doi.org/10.1158/1078-0432.22462056.v1
https://doi.org/10.1158/1078-0432.22462056.v1
Autor:
Robert L. Ferris, Robert M. Hershberg, Jonas T. Johnson, Dwight E. Heron, David A. Clump, Umamaheswar Duvvuri, Seungwon Kim, James Ohr, Julie E. Bauman, James Kyle Bryan, Raghvendra M. Srivastava, Sandra P. Gibson, Benjamin A. Kansy, Gulidanna Shayan
Purpose: The response rate of patients with head and neck squamous cell carcinoma (HNSCC) to cetuximab therapy is only 15% to 20%, despite frequent EGFR overexpression. Because immunosuppression is common in HNSCC, we hypothesized that adding a proin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3bf8d55a3ee70fa75af1837e9fb3ad03
https://doi.org/10.1158/1078-0432.c.6524994
https://doi.org/10.1158/1078-0432.c.6524994
Autor:
Robert L. Ferris, Robert M. Hershberg, Jonas T. Johnson, Dwight E. Heron, David A. Clump, Umamaheswar Duvvuri, Seungwon Kim, James Ohr, Julie E. Bauman, James Kyle Bryan, Raghvendra M. Srivastava, Sandra P. Gibson, Benjamin A. Kansy, Gulidanna Shayan
Supplementary figure S1 & supplementary table S1 legends
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b2b3a0cd4d1a4c7fbdf0df858984385a
https://doi.org/10.1158/1078-0432.22462053.v1
https://doi.org/10.1158/1078-0432.22462053.v1
Autor:
Asif Khalid, Nathan Bahary, Sharon Winters, Lauren Stitt, Adam C. Olson, Richard S. Hoehn, Adam Slivka, Kenneth K. Lee, Ritu Sarkaria, James Ohr, Caroline J. Rieser, Randal E. Brand, Steve Burton, Vikram C. Gorantla, David L. Bartlett, Kenneth E. Fasanella, Jennifer Chennat, Rohit Das, Aatur D. Singhi, Herbert J. Zeh, Anuradha Krishnamurthy, Melissa E. Hogg, John C. Rhee, Susannah G. Ellsworth, Kevin McGrath, Alessandro Paniccia, Amer H. Zureikat
Publikováno v:
Ann Surg Oncol
AIMS: National studies have demonstrated disparities in the treatment and survival of pancreatic cancer patients based on socioeconomic status (SES). This study aimed to identify specific differences in perioperative management and outcomes based on
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c3c0bb1cd0369526ac01d1cfb756ada2
https://doi.org/10.1245/s10434-021-09594-8
https://doi.org/10.1245/s10434-021-09594-8
Autor:
Marion A. Hughes, Shaum Sridharan, David A. Clump, James Ohr, Mark Kubik, Mario G. Solari, Barton F. Branstetter, Umamaheswar Duvvuri, Heath D. Skinner, Marci Lee Nilsen, Jennifer L. Anderson, Jonas T. Johnson, Raja R. Seethala, Seungwon Kim, Dan P. Zandberg, Katie S. Traylor, Harish Dharmarajan, Simion I. Chiosea, Robert L. Ferris
Publikováno v:
Head & Neck
Multidisciplinary conferences (MDC) are an important component of head and neck oncologic care including diagnosis, treatment, and survivorship. Virtual MDC allows for improved collaboration between providers at distant sites and proper allocation of
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::230470a1b48503a0a2c3b009510aac6d
https://doi.org/10.1002/hed.26195
https://doi.org/10.1002/hed.26195
Autor:
Robert L. Ferris, Jessica Moskovitz, Sheryl Kunning, Ayana T. Ruffin, Carly Reeder, James Ohr, William E. Gooding, Seungwon Kim, Brian J. Karlovits, Dario A.A. Vignali, Umamaheswar Duvvuri, Jonas T. Johnson, Daniel Petro, Dwight E. Heron, David A. Clump, Tullia C. Bruno, Julie E. Bauman
Publikováno v:
Clin Cancer Res
Purpose: Concurrent radiotherapy with cetuximab, an anti-EGFR mAb, is a standard treatment for locally advanced head and neck squamous carcinoma (HNSCC). Cytotoxic T lymphocyte antigen-4–positive (CTLA-4+) regulatory T cells (Treg) dampen cellular
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1b8e0c45e8ea3a1fb53d59db2ef9ccb8
https://europepmc.org/articles/PMC9164766/
https://europepmc.org/articles/PMC9164766/
Autor:
Marco Antonio Mascarella, Tolani Olonisakin, Purva Rumde, Varun Vendra, Melonie Nance, Seungwon Kim, Mark Kubik, Shaum Sridharan, Robert Ferris, Moon Fenton, Daniel Clayburgh, James Ohr, Malabika Sen, Sonali Joyce, James Herman, Jennifer Grandis, Dan Zandberg, Umamaheswar Duvvuri
Publikováno v:
Cancer Research. 83:4338-4338
Purpose: Neoadjuvant targeted therapy provides a brief, preoperative ‘window of opportunity’ that can be exploited to individualize cancer care based on treatment response. We investigated whether response to neoadjuvant therapy during the preope
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb7af64c0ef46c7039536caf849c4899
https://doi.org/10.1158/1538-7445.am2023-4338
https://doi.org/10.1158/1538-7445.am2023-4338